Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Gains from Investment Securities: 2016-2025

Historic Gains from Investment Securities for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to -$19,000.

  • Collegium Pharmaceutical's Gains from Investment Securities fell 100.12% to -$19,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 87.49%. This contributed to the annual value of $52.1 million for FY2024, which is 115.20% up from last year.
  • Collegium Pharmaceutical's Gains from Investment Securities amounted to -$19,000 in Q3 2025, which was up 94.69% from -$358,000 recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Gains from Investment Securities registered a high of $23.0 million during Q2 2024, and its lowest value of -$2.9 million during Q4 2024.
  • For the 3-year period, Collegium Pharmaceutical's Gains from Investment Securities averaged around $7.5 million, with its median value being $7.3 million (2023).
  • Per our database at Business Quant, Collegium Pharmaceutical's Gains from Investment Securities surged by 1,804.13% in 2023 and then tumbled by 142.16% in 2024.
  • Collegium Pharmaceutical's Gains from Investment Securities (Quarterly) stood at $2.3 million in 2021, then plummeted by 84.27% to $363,000 in 2022, then skyrocketed by 1,804.13% to $6.9 million in 2023, then plummeted by 142.16% to -$2.9 million in 2024, then crashed by 100.12% to -$19,000 in 2025.
  • Its Gains from Investment Securities was -$19,000 in Q3 2025, compared to -$358,000 in Q2 2025 and $10.6 million in Q1 2025.